Skip to main content
Home
Knowledge Base
for the National TB Elimination Program - NTEP
x

Main navigation

  • Home +
    • About Us
  • Curriculum +
    • Content view
    • List View
  • Knowledge Map +
    • Knowledge Map Summary
  • Documents
  • Page Library +
    • Content Page Summary
x

STLS: Follow up of TB patients

  1. Home ›
  2. ›
  3. STLS: Follow up of TB patients
Fullscreen
  • Follow up sputum examination

    Content

    Follow-up Sputum Examination is useful for the clinical follow-up which helps in assessing the response to treatment, and to establish cure or failure at the end of treatment.

    Significance:

    The most important tool in the diagnosis of tuberculosis is direct microscopic examination of appropriately stained sputum specimens for acid-fast bacilli (AFB). The technique is simple and inexpensive, and used in the detection of tuberculosis. Sputum microscopy is also useful for the clinical follow up which helps in assessing the response to treatment, and to establish cure or failure at the end of treatment.

    Schedule

    In case of Drug-sensitive Tuberculosis (DS-TB), the follow-up is done at the end of Intensive Phase (IP) and at the end of Continuation Phase (CP).

    In case of Drug-resistant Tuberculosis (DR-TB), the follow up schedule is different for all the three regimen described below:

    Isoniazid (H) mono/ poly DR-TB regimen

    • Monthly from month 3 onwards, till the end of treatment
    • Conduct sputum microscopy within 7 days, if the smear at month 4 or later is positive to rapidly ascertain bacteriological conversion/ reversion.

    Shorter oral Bedaquiline-containing Multidrug-Resistant (MDR)/ Rifampicin-Resistant (RR)-TB regimen

    • Monthly from 3rd month onwards, till end of IP
    • Monthly in extended IP, only if previous month S+ve
    • Conduct sputum microscopy within 7 days, if the smear at 6 months is positive to rapidly ascertain bacteriological conversion/ reversion.

    Longer oral M/ XDR-TB regimen

    • With culture at Culture and Drug Susceptibility (C&DST) lab
    • Conduct sputum microscopy within 7 days if any smear at 6 month or later is positive to rapidly ascertain bacteriological conversion/ reversion.

     

    Post Treatment Follow-Up

    After completion of treatment, the patients should be followed-up at the end of 6, 12, 18 & 24 months for detecting recurrence of TB at the earliest. In presence of any clinical symptoms and/or cough, sputum microscopy and/or culture should be considered. This is important in detecting recurrence of TB at the earliest.

     

    Implications

    The sputum follow-up examination is a quick and reliable method which helps in monitoring the progress of the treatment and gives an early indication of any recurrence.

     
    Resources
    • Training Modules (1-4) for Programme Managers & Medical Officers, NTEP, CTD, MoHFW, GoI, 2020.
    • Guidelines for Programmatic Management of Drug-resistant Tuberculosis in India, NTEP. CTD, MoHFW, 2021.

    Assessment

     



    Question 1


    Answer 1


    Answer 2


    Answer 3


    Answer 4


    Correct Answer


    Correct Explanation


    Page id


    Part of Pre-Test


    Part of Post-Test


    The follow-up in all oral longer regimen should be done with culture at C&DST Lab


    True


    False


     


     


    1


    The follow-up of sputum is done with culture at C&DST lab

     


     


    Yes


    Yes

     

     

  • Long Term Post-treatment follow up of TB patients

    Content

    After completion of TB treatment, all patients should be followed up at the end of

    • 6 months,
    • 12 months,
    • 18 months &
    • 24 months

    TB patients at the follow up should be screened for any clinical symptoms and/or cough. If found positive on screening, then sputum microscopy and/or culture should be considered. This is important in detecting the recurrence of TB at the earliest.

    After completion of TB treatment, if the patient has not developed any clinical symptoms and/or cough and also if the microscopy remains negative during their follow up, then the patient is considered as “Relapse Free Cure from TB.”

     

  • Management of Patients with Treatment Interruptions

    Content

    Treatment interruption is defined as a patient-initiated episode in which the patient discontinues TB treatment. All efforts must be made to ensure that TB patients do not interrupt treatment or are not lost to follow-up. Action should be taken to promptly retrieve patients who fail to come for their daily dose by the treatment supporter

     

    The management of treatment interruptions is made based on the following criteria:

    i. Type of case: Whether new, relapse or failure

    ii. Duration of treatment taken: Less than one month/ more than one month. This helps in assessing the risk of the presence of drug resistance.

    iii. Duration of Interruption: Less than one month/ more than a month.

    If treatment interruption is more than one month, the outcome is declared as ‘lost to follow up’.

    If a patient returns to the health facility after interrupting treatment for more than one month, the patient sample needs to be subjected to Drug Susceptibility Testing (DST) to determine resistance/ sensitivity status to anti-TB drugs.

    In case the interruption is for less than one month, the same treatment regimen is completed to complete all doses.

     

    Modes of Retrieval

    TB treatment is supervised by a trained treatment supporter (a health worker, family member or community volunteer). The residential address is verified for all TB patients by home visits. However, in case of treatment interruption, patient retrieval action is required.

     

    Retrieval can be done by the following modes:

    1. Retrieval of patients interrupting treatment within 24 hours of discontinuation is done by the Treatment Supporter (TS) or Accredited Social Health Activist (ASHA)/ Auxilliary Nurse Midwife (ANM)/ Multipurpose Worker (MPW). The reason for interruptions should be reviewed carefully and efforts made to counsel and bring the patient back for treatment.

    2. If the TS is not successful in retrieving such patients, it should be reported to the next higher level of supervisors, like Senior Treatment Supervisor (STS), and they should take all efforts to counsel and retrieve the patient.

    3. If the patient interrupts treatment on more than one occasion, the Medical Officer of the Peripheral Health Institute (MO-PHI) should visit the patient’s home. The MO-PHI should give intensive counselling to the patient and may provide additional support to continue the treatment without interruption.

    4. Innovative use of information and communication technologies for treatment adherence monitoring through 99 DOTS, Medication Event Reminder Monitor (MERM), etc. are also beneficial in finding missed doses and initiating retrieval action by the health staff.

     

    Resources

    1. Training Modules (1-4) for Programme Managers and Medical Officers.

    2. Guidelines for PMDT in India, 2021.

     

    Assessment

    Question​ Answer 1​ Answer 2​ Answer 3​ Answer 4​ Correct answer​ Correct explanation​ Page id​ Part of Pre-test​ Part of Post-test​
    If treatment interruption is more than one month, the outcome is declared as ‘lost to follow-up'. True False     1 If treatment interruption is more than one month, the outcome is declared as ‘lost to follow-up'. ​ Yes Yes
© 2026 Knowledge Base, All rights reserved.

User account menu

  • Log in
⇡